Regeneron Pharmaceuticals, Inc. (REGN): Price and Financial Metrics

Regeneron Pharmaceuticals, Inc. (REGN): $504.42

4.73 (+0.95%)

POWR Rating

Component Grades













Add REGN to Watchlist
Sign Up

Industry: Biotech


of 493

in industry

REGN Stock Summary

  • Regeneron Pharmaceuticals Inc's market capitalization of $53,532,738,611 is ahead of 95.34% of US-listed equities.
  • REGN's went public 30.07 years ago, making it older than 83.57% of listed US stocks we're tracking.
  • With a year-over-year growth in debt of 277.6%, Regeneron Pharmaceuticals Inc's debt growth rate surpasses 95.23% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Regeneron Pharmaceuticals Inc, a group of peers worth examining would be VRTX, SGEN, CDNS, BGNE, and SNPS.
  • REGN's SEC filings can be seen here. And to visit Regeneron Pharmaceuticals Inc's official web site, go to

REGN Stock Price Chart Interactive Chart >

Price chart for REGN

REGN Price/Volume Stats

Current price $504.42 52-week high $664.64
Prev. close $499.69 52-week low $441.00
Day low $497.40 Volume 858,831
Day high $506.73 Avg. volume 1,012,603
50-day MA $475.32 Dividend yield N/A
200-day MA $540.62 Market Cap 54.04B

Regeneron Pharmaceuticals, Inc. (REGN) Company Bio

Regeneron Pharmaceuticals is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL-cholesterol and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, and atopic dermatitis. The company was founded in 1988 and is based in Tarrytown, New York.

REGN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$504.42$347.37 -30%

Below please find a table outlining a discounted cash flow forecast for REGN, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Regeneron Pharmaceuticals Inc ranked in the 45th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 30%. In terms of the factors that were most noteworthy in this DCF analysis for REGN, they are:

  • Interest coverage, a measure of earnings relative to interest payments, is 67.97 -- which is good for besting 92% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
  • The business' balance sheet reveals debt to be 4% of the company's capital (with equity being the remaining amount). Approximately only 16.88% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • REGN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 44.25% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

MEDP, TMO, ICLR, AMED, and PRAH can be thought of as valuation peers to REGN, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.

REGN Latest News Stream

Event/Time News Detail
Loading, please wait...

REGN Latest Social Stream

Loading social stream, please wait...

View Full REGN Social Stream

Latest REGN News From Around the Web

Below are the latest news stories about Regeneron Pharmaceuticals Inc that investors may wish to consider to help them evaluate REGN as an investment opportunity.

Doctor on J&J vaccine: ‘You have a much higher risk of getting a blood clot if you smoke’

Dr. Elizabeth Clayborne, Adjunct Assistant Professor of Emergency Medicine at the University of Maryland School of Medicine and Emergency Physician at UM Prince George’s Hospital Center, joins Yahoo Finance’s Kristin Myers and Alexis Christoforous to discuss the latest on the coronavirus.

Yahoo | April 19, 2021

Market Recap With Jim Cramer: Coinbase and Cathie Wood

TheStreet recaps the best stories with Jim Cramer from the past week including Regeneron's COVID treatment, the impact of Apple products, and more.

Yahoo | April 19, 2021

3 Cathie Wood Stocks You Can Buy at a Bargain Right Now

When Cathie Wood talks, investors listen. The founder of Ark Invest has successfully predicted stock market stars -- one of her top holdings is Tesla. Now, here's some great news for all of us who want to follow this investment superstar's lead: Right now, you can buy three of the biggest holdings in her Ark Genomic Revolution ETF at a bargain.

Yahoo | April 17, 2021

Could Vir Biotechnology Be a Millionaire Maker Stock?

Vir Biotechnology (NASDAQ: VIR) may be weeks away from commercializing its very first product. The clinical-stage biotech company and partner GlaxoSmithKline late last month requested Emergency Use Authorization (EUA) for their investigational COVID-19 treatment. In more good news, GlaxoSmithKline recently expanded its collaboration with Vir to include the development of potential treatments for respiratory viruses including influenza.

Yahoo | April 17, 2021

Vaccinating kids will be very important in getting to herd immunity: Expert

Kristen Choi, PhD, MS, RN, Assistant Professor, UCLA School of Nursing, joins Yahoo Finance’s Kristin Myers and Alexis Christoforous to discuss the latest on the coronavirus.

Yahoo | April 16, 2021

Read More 'REGN' Stories Here

REGN Price Returns

1-mo 6.49%
3-mo -6.98%
6-mo -12.39%
1-year -11.19%
3-year 60.52%
5-year 23.16%
YTD 4.41%
2020 28.66%
2019 0.53%
2018 -0.65%
2017 2.42%
2016 -32.38%

Continue Researching REGN

Want to see what other sources are saying about Regeneron Pharmaceuticals Inc's financials and stock price? Try the links below:

Regeneron Pharmaceuticals Inc (REGN) Stock Price | Nasdaq
Regeneron Pharmaceuticals Inc (REGN) Stock Quote, History and News - Yahoo Finance
Regeneron Pharmaceuticals Inc (REGN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.1175 seconds.